Previous exposure to THC alters the reinforcing efficacy and anxiety-related effects of cocaine in rats

Neuropsychopharmacology

Volumn 32, Issue 3, 2007, Pages 646-657

  Panlilio, Leigh V ^a   Solinas, Marcello ^b   Matthews, Stephanie A ^a   Goldberg, Steven R ^a  

^a NATIONAL INSTITUTE ON DRUG ABUSE   (United States)

^b UNIVERSITÉ DE POITIERS   (France)

Author keywords

Gateway drug hypothesis; Heroin; Light dark test; Open field; Progressive ratio schedule; Self administration

Indexed keywords

COCAINE; DIAMORPHINE; TETRAHYDROCANNABINOL;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANXIETY; ARTICLE; COCAINE DEPENDENCE; CONTROLLED STUDY; CROSS TOLERANCE; DISEASE MODEL; EXPOSURE; INJECTION; LIGHT DARK CYCLE; LOCOMOTION; MOTOR DYSFUNCTION; NONHUMAN; OPEN FIELD BEHAVIOR; PRIORITY JOURNAL; RAT; REINFORCEMENT;

ANALGESICS, NON-NARCOTIC; ANIMALS; ANXIETY; BEHAVIOR, ANIMAL; CHOICE BEHAVIOR; COCAINE; CONDITIONING, OPERANT; DOPAMINE UPTAKE INHIBITORS; DRUG INTERACTIONS; MOTOR ACTIVITY; RATS; RATS, SPRAGUE-DAWLEY; REACTION TIME; REINFORCEMENT (PSYCHOLOGY); REINFORCEMENT SCHEDULE; SELF ADMINISTRATION; TETRAHYDROCANNABINOL;

EID: 33847027722     PISSN: 0893133X     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.npp.1301109     Document Type: Article

References (76)

1. Amalric M, Koob GF (1985). Low doses of methylnaloxonium in the nucleus accumbens antagonize hyperactivity induced by heroin in the rat. Pharmacol Biochem Behav 23: 411-415.
2. Arevalo C, de Miguel R, Hernandez-Tristan R (2001). Cannabinoid effects on anxiety-related behaviours and hypothalamic neurotransmitters. Pharmacol Biochem Behav 70: 123-131.
3. Arnold JC, Topple AN, Hunt GE, McGregor IS (1998). Effects of pre-exposure and co-administration of the cannabinoid receptor agonist CP 55,940 on behavioral sensitization to cocaine. Eur J Pharmacol 354: 9-16.
4. Arnold JM, Roberts DC (1997). A critique of fixed and progressive ratio schedules used to examine the neural substrates of drug reinforcement. Pharmacol Biochem Behav 57: 441-447.
5. Baumrind D (1983). Specious causal attributions in the social sciences: the reformulated stepping-stone theory of heroin use as exemplar. J Pers Soc Psychol 45: 1289-1298.
6. Berrendero F, Maldonado R (2002). Involvement of the opioid system in the anxiolytic-like effects induced by Delta(9)-tetrahydrocannabinol. Psychopharmacology 163: 111-117.
7. Cadoni C, Pisanu A, Solinas M, Acquas E, Di Chiara G (2001). Behavioural sensitization after repeated exposure to Delta 9-tetrahydrocannabinol and cross-sensitization with morphine. Psychopharmacology 158: 259-266.
8. Caille S, Parsons LH (2003). SR141716A reduces the reinforcing properties of heroin but not heroin-induced increases in nucleus accumbens dopamine in rats. Eur J Neurosci 18: 3145-3149.
9. Carey RJ, DePalma G, Damianopoulos E (2005a). Evidence for Pavlovian conditioning of cocaine-induced responses linked to emotional behavioral effects. Pharmacol Biochem Behav 80: 123-134.
10. Carey RJ, DePalma G, Damianopoulos E (2005b). Acute and chronic cocaine behavioral effects in novel versus familiar environments: open-field familiarity differentiates cocaine locomotor stimulant effects from cocaine emotional behavioral effects. Behav Brain Res 158: 321-330.
11. Cossu G, Ledent C, Fattore L, Imperato A, Bohme GA, Parmentier M et al (2001). Cannabinoid CB1 receptor knockout mice fail to self-administer morphine but not other drugs of abuse. Behav Brain Res 118: 61-65.
12. Costall B, Jones BJ, Kelly ME, Naylor RJ, Tomkins DM (1989a). Exploration of mice in a black and white test box: validation as a model of anxiety. Pharmacol Biochem Behav 32: 777-785.
13. Costall B, Kelly ME, Naylor RJ, Onaivi ES (1989b). The actions of nicotine and cocaine in a mouse model of anxiety. Pharmacol Biochem Behav 33: 197-203.
14. DeVries AC, Pert A (1998). Conditioned increases in anxiogenic-like behavior following exposure to contextual stimuli associated with cocaine are mediated by corticotropin-releasing factor. Psychopharmacology 137: 333-340.
15. DeVries TJ, Homberg JR, Binnekade R, Raasø H, Schoffelmeer ANM (2003). Cannabinoid modulation of the reinforcing and motivational properties of heroin and heroin-associated cues in rats. Psychopharmacology 168: 164-169.
16. Diana M, Melis M, Muntoni AL, Gessa GL (1998). Mesolimbic dopaminergic decline after cannabinoid withdrawal. Proc Natl Acad Sci USA 95: 10269-10273.
17. Ellickson PL, Hays RD, Bell RM (1992). Stepping through the drug use sequence: longitudinal scalogram analysis of initiation and regular use. J Abnorm Psychol 101: 441-451.
18. Ettenberg A (2004). Opponent process properties of self-administered cocaine. Neurosci Biobehav Rev 27: 721-728.
19. Ettenberg A, Geist TD (1991). Animal model for investigating the anxiogenic effects of self-administered cocaine. Psychopharmacology 103: 455-461.
20. Ettenberg A, Geist TD (1993). Qualitative and quantitative differences in the operant runway behavior of rats working for cocaine and heroin reinforcement. Pharmacol Biochem Behav 44: 191-198.
21. Ettenberg A, Raven MA, Danluck DA, Necessary BD (1999). Evidence for opponent-process actions of intravenous cocaine. Pharmacol Biochem Behav 64: 507-512.
22. Fattore L, Martellotta MC, Cossu G, Mascia MS, Fratta W (1999). CB1 cannabinoid receptor agonist WIN 55,212-2 decreases intravenous cocaine self-administration in rats. Behav Brain Res 104: 141-146.
23. Fergusson DM, Horwood LJ (2000). Does cannabis use encourage other forms of illicit drug use? Addiction 95: 505-520.
24. File SE (1992). Behavioural detection of anxiolytic action. In: Elliot JM, Heal DJ, Marsden CA (eds). Experimental Approaches to Anxiety and Depression. Wiley: New York. pp 25-44.
25. File SE, Seth P (2003). A review of 25 years of the social interaction test. Eur J Pharmacol 463: 35-53.
26. Fontana DJ, Commissaris RL (1989). Effects of cocaine on conflict behavior in the rat. Life Sci 45: 819-827.
27. Genn RF, Tucci S, Marco EM, Viveros MP, File SE (2004). Unconditioned and conditioned anxiogenic effects of the cannabinoid receptor agonist CP 55,940 in the social interaction test. Pharmacol Biochem Behav 77: 567-573.
28. Gerber GJ, Wise RA (1989). Pharmacological regulation of intravenous cocaine and heroin self-administration in rats: a variable dose paradigm. Pharmacol Biochem Behav 32: 527-531.
29. Gorriti MA, Ferrer B, del Arco I, Bermudez-Silva FJ, de Diego Y, Fernandez-Espejo E et al (2005). Acute delta9-tetrahydrocannabinol exposure facilitates quinpirole-induced hyperlocomotion. Pharmacol Biochem Behav 81: 71-77.
30. Gorriti MA, Rodriguez de Fonseca F, Navarro M, Palomo T (1999). Chronic (-)-delta9-tetrahydrocannabinol treatment induces sensitization to the psychomotor effects of amphetamine in rats. Eur J Pharmacol 365: 133-142.
31. Griffiths RR, Findley JD, Brady JV, Dolan-Gutcher K, Robinson WW (1975). Comparison of progressive-ratio performance maintained by cocaine, methylphenidate and secobarbital. Psychopharmacologia 43: 81-83.
32. Grossen NE, Kelley MJ (1972). Species-specific behavior and acquisition of avoidance behavior in rats. J Comp Physiol Psychol 81: 307-310.
33. Hascoët M, Bourin M (1998). A new approach to the light/dark test procedure in mice. Pharmacol Biochem Behav 60: 645-653.
34. Hoffman AF, Oz M, Caulder T, Lupica CR (2003). Functional tolerance and blockade of long-term depression at synapses in the nucleus accumbens after chronic cannabinoid exposure. J Neurosci 23: 4815-4820.
35. Kandel D, Faust R (1975). Sequence and stages in patterns of adolescent drug use. Arch Gen Psychiat 32: 923-932.
36. Kandel D (1975). Stages in adolescent involvement in drug use. Science 190: 912-914.
37. Kandel DB (2003). Does marijuana use cause the use of other drugs? J Am Med Assoc 289: 482-483.
38. Ko MC, Terner J, Hursh S, Woods JH, Winger G (2002). Relative reinforcing effects of three opioids with different durations of action. J Pharmacol Exp Ther 301: 698-704.
39. Lamarque S, Taghzouti K, Simon H (2001). Chronic treatment with Delta(9)-tetrahydrocannabinol enhances the locomotor response to amphetamine and heroin. Implications for vulnerability to drug addiction. Neuropharmacology 41: 118-129.
40. Lynskey MT, Heath AC, Bucholz KK, Slutske WS, Madden PA, Nelson EC et al (2003). Escalation of drug use in early-onset cannabis users vs co-twin controls. J Am Med Assoc 289: 427-433.
41. Marco EM, Perez-Alvarez L, Borcel E, Rubio M, Guaza C, Ambrosio E et al (2004). Involvement of 5-HT1A receptors in behavioural effects of the cannabinoid receptor agonist CP 55,940 in male rats. Behav Pharmacol 15: 21-27.
42. Marin S, Marco E, Biscaia M, Fernandez B, Rubio M, Guaza C et al (2003). Involvement of the kappa-opioid receptor in the anxiogenic-like effect of CP 55,940 in male rats. Pharmacol Biochem Behav 74: 649-656.
43. Martin M, Ledent C, Parmentier M, Maldonado R, Valverde O (2000). Cocaine, but not morphine, induces conditioned place preference and sensitization to locomotor responses in CB1 knockout mice. Eur J Neurosci 12: 4038-4046.
44. Mato S, Robbe D, Puente N, Grandes P, Manzoni OJ (2005). Presynaptic homeostatic plasticity rescues long-term depression after chronic Delta9-tetrahydrocannabinol exposure. J Neurosci 25: 11619-11627.
45. McLaughlin PJ, Lu D, Winston KM, Thakur G, Swezey LA, Makriyannis A et al (2005). Behavioral effects of the novel cannabinoid full agonist AM 411. Pharmacol Biochem Behav 81: 78-88.
46. Moreno M, Lopez-Moreno JA, Rodriguez de Fonseca F, Navarro M (2005). Behavioural effects of quinpirole following withdrawal of chronic treatment with the CB1 agonist, HU-210, in rats. Behav Pharmacol 16: 441-446.
47. National Research Council (2003). Guidelines for the Care and Use of Mammals in Neuroscience and Behavioral Research. National Academics Press: Washington, DC.
48. Navarro M, Carrera MR, Fratta W, Valverde O, Cossu G, Fattore L et al (2001). Functional interaction between opioid and cannabinoid receptors in drug self-administration. J Neurosci 21: 5344-5350.
49. Norwood CS, Cornish JL, Mallet PE, McGregor IS (2003). Pre-exposure to the cannabinoid receptor agonist CP 55,940 enhances morphine behavioral sensitization and alters morphine self-administration in Lewis rats. Eur J Pharmacol 465: 105-114.
50. Onaivi ES, Martin BR (1989). Neuropharmacological and physiological validation of a computer-controlled two-compartment black and white box for the assessment of anxiety. Prog Neuro-Psychopharmacol Biol Psychiat 13: 963-976.
51. Paine TA, Jackman SL, Olmstead MC (2002). Cocaine-induced anxiety: alleviation by diazepam, but not buspirone, dimenhydrinate or diphenhydramine. Behav Pharmacol 13: 511-523.
52. Panlilio LV, Goldberg SR, Gilman JP, Jufer R, Cone EJ, Schindler CW (1998). Effects of delivery rate and non-contingent infusion of cocaine on cocaine self-administration in rhesus monkeys. Psychopharmacology 137: 253-258.
53. Panlilio LV, Katz JL, Pickens RW, Schindler CW (2003). Variability of drug self-administration in rats. Psychopharmacology 167: 9-19.
54. Panlilio LV, Schindler CW (2000). Self-administration of remifentanil, an ultra-short acting opioid, under continuous and progressive-ratio schedules of reinforcement in rats. Psychopharmacology 150: 61-66.
55. Pich EM, Samanin R (1989). A two-compartment exploratory model to study anxiolytic/anxiogenic effects of drugs in the rat. Pharmacol Res 21: 595-602.
56. Pontieri FE, Monnazzi P, Scontrini A, Buttarelli FR, Patacchioli FR (2001). Behavioral sensitization to heroin by cannabinoid pretreatment in the rat. Eur J Pharmacol 421: R1-R3.
57. Prut L, Belzung C (2003). The open field as a paradigm to measure the effects of drugs on anxiety-like behaviors: a review. Eur J Pharmacol 463: 3-33.
58. Ramos A, Correia EC, Izidio GS, Bruske GR (2003). Genetic selection of two new rat lines displaying different levels of anxiety-related behaviors. Behav Genet 33: 657-668.
59. Ramos A, Mellerin Y, Mormede P, Chaouloff F (1998). A genetic and multifactorial analysis of anxiety-related behaviours in Lewis and SHR intercrosses. Behav Brain Res 96: 195-205.
60. Rodriguez de Fonseca F, Carrera MRA, Navarro M, Koob GF, Weiss F (1997). Activation of corticotropin-releasing factor in the limbic system during cannabinoid withdrawal. Science 276: 2050-2054.
61. Rodriguez de Fonseca F, Rubio P, Menzaghi F, Merlo-Pich E, Rivier J, Koob GF et al (1996). Corticotropin-releasing factor (CRF) antagonist [D-Phe12,Nle21,38,C alpha MeLeu37]CRF attenuates the acute actions of the highly potent cannabinoid receptor agonist HU-210 on defensive-withdrawal behavior in rats. J Pharmacol Exp Ther 276: 56-64.
62. Rogerio R, Takahashi RN (1992). Anxiogenic properties of cocaine in the rat evaluated with the elevated plus-maze. Pharmacol Biochem Behav 43: 631-633.
63. Rubino T, Vigano D, Massi P, Parolaro D (2003). Cellular mechanisms of Delta 9-tetrahydrocannabinol behavioural sensitization. Eur J Neurosci 17: 325-330.
64. Shearman GT, Lal H (1981). Discriminative stimulus properties of cocaine related to an anxiogenic action. Prog Neuropsychopharmacol 5: 57-63.
65. Solinas M, Panlilio LV, Antoniou K, Pappas LA, Goldberg SR (2003). The cannabinoid CB1 antagonist N-piperidinyl-5-(4-chlorophenyl)-1-(2,4- dichlorophenyl)-4-methylpyrazole-3-carboxamide (SR-141716A) differentially alters the reinforcing effects of heroin under continuous reinforcement, fixed ratio, and progressive ratio schedules of drug self-administration in rats. J Pharmacol Exp Ther 306: 93-102.
66. Solinas M, Panlilio LV, Goldberg SR (2004). Exposure to delta-9-tetrahydrocannabinol (THC) increases subsequent heroin taking but not heroin's reinforcing efficacy: a self-administration study in rats. Neuropsychopharmacology 29: 1301-1311.
67. Solinas M, Panlilio LV, Tanda G, Makriyannis A, Matthews SA, Goldberg SR (2005). Cannabinoid agonists but not inhibitors of endogenous cannabinoid transport or metabolism enhance the reinforcing efficacy of heroin in rats. Neuropsychopharmacology 30: 2046-2057.
68. Soria G, Mendizabal V, Tourino C, Robledo P, Ledent C, Parmentier M et al (2005). Lack of CB1 cannabinoid receptor impairs cocaine self-administration. Neuropsychopharmacology 30: 1670-1680.
69. Spealman RD (1979). Behavior maintained by termination of a schedule of self-administered cocaine. Science 204: 1231-1233.
70. Stafford D, LeSage MG, Glowa JR (1998). Progressive-ratio schedules of drug delivery in the analysis of drug self-administration: a review. Psychopharmacology 139: 169-184.
71. Tanda G, Loddo P, Di Chiara G (1999). Dependence of mesolimbic dopamine transmission on delta9-tetrahydrocannabinol. Eur J Pharmacol 376: 23-26.
72. Tanda G, Munzar P, Goldberg SR (2000). Self-administration behavior is maintained by the psychoactive ingredient of marijuana in squirrel monkeys. Nat Neurosci 3: 1073-1074.
73. Treit D, Fundytus M (1988). Thigmotaxis as a test for anxiolytic activity in rats. Pharmacol Biochem Behav 31: 959-962.
74. Tsibulsky VL, Norman AB (1999). Satiety threshold: a quantitative model of maintained cocaine self-administration. Brain Res 839: 85-93.
75. Vendruscolo LF, Takahashi RN, Bruske GR, Ramos A (2003). Evaluation of the anxiolytic-like effect of NKP608, a NK1-receptor antagonist, in two rat strains that differ in anxiety-related behaviors. Psychopharmacology 170: 287-293.
76. Yang XM, Gorman AL, Dunn AJ, Goeders NE (1992). Anxiogenic effects of acute and chronic cocaine administration: neurochemical and behavioral studies. Pharmacol Biochem Behav 41: 643-645.